The Emerald Trial is a Phase III clinical trial evaluating the efficacy of elacestrant, an oral selective ER degrader (SERD), in treating patients with ER-positive, HER2-negative advanced or metastatic BC. This evidence concerns the gene ERBB2 and breast cancer.